ERS 2026: GB-0895 clinical results show potential of next-gen anti-TSLP for asthma

Phase 1positiveGB-0895Positive

AI Analysis

Summary

Generate: Biomedicines presented pharmacodynamics and safety results from an ongoing Phase 1 study of GB-0895, a next-generation anti-TSLP therapeutic candidate, at ERS 2026.

Clinical Trial Data

Phase

Phase 1

NCT ID

NCT07116889

Outcome Details

Pharmacodynamics and safety results presented

Importance:5/10

Sentiment:

0.60

asthmaanti-TSLPPhase 1pharmacodynamicssafetyconference presentation

Read the original article

Published by Pharmaceutical Technology on September 9, 2026 2:36 PM

Read Original